Skip to main content

Candidiasis, Invasive

3
Pipeline Programs
4
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
1
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 4 programs with unclassified modality

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Astellas
AstellasChina - Shenyang
1 program
1
IsavuconazolePhase 3Small Molecule
MSD
MSDIreland - Ballydine
1 program
1
CaspofunginPhase 21 trial
Active Trials
NCT01945281Terminated51Est. Feb 2018
Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
1 program
1
CaspofunginPhase 2
Scynexis
ScynexisJERSEY CITY, NJ
2 programs
SCY-078PHASE_31 trial
SCY-078PHASE_31 trial
Active Trials
NCT03363841Completed30Est. May 2023
NCT05178862Terminated68Est. Dec 2025

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
ScynexisSCY-078
ScynexisSCY-078
MSDCaspofungin

Clinical Trials (3)

Total enrollment: 149 patients across 3 trials

NCT05178862ScynexisSCY-078

A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole

Start: Aug 2022Est. completion: Dec 202568 patients
Phase 3Terminated
NCT03363841ScynexisSCY-078

Open-Label Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) in Patients With Candidiasis Caused by Candida Auris (CARES)

Start: Nov 2017Est. completion: May 202330 patients
Phase 3Completed
NCT01945281MSDCaspofungin

Safety, Tolerability, and Efficacy of Caspofungin Versus Amphotericin B Deoxycholate in the Treatment of Invasive Candidiasis in Neonates and Infants (MK-0991-064)

Start: Jan 2014Est. completion: Feb 201851 patients
Phase 2Terminated

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.